Madrigal Pharmaceuticals Inc
NASDAQ:MDGL

Watchlist Manager
Madrigal Pharmaceuticals Inc Logo
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Watchlist
Price: 293.64 USD 7.64% Market Closed
Market Cap: 6.4B USD

Profitability Summary

Madrigal Pharmaceuticals Inc's profitability score is 41/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

41/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

41/100
Profitability
Score
41/100
Profitability
Score

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Madrigal Pharmaceuticals Inc

Revenue
76.8m USD
Cost of Revenue
-2.8m USD
Gross Profit
74m USD
Operating Expenses
-622.1m USD
Operating Income
-548.1m USD
Other Expenses
29.4m USD
Net Income
-518.7m USD

Margins Comparison
Madrigal Pharmaceuticals Inc Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
US
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
6.1B USD
96%
-713%
-675%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
-17 527%
-21 040%
US
Abbvie Inc
NYSE:ABBV
303.2B USD
67%
28%
9%
US
Amgen Inc
NASDAQ:AMGN
146.3B USD
60%
19%
13%
US
Gilead Sciences Inc
NASDAQ:GILD
114.4B USD
78%
38%
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
108.8B USD
86%
40%
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
-370%
-392%
AU
CSL Ltd
ASX:CSL
132.9B AUD
52%
26%
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
75B USD
87%
30%
34%
US
Seagen Inc
F:SGT
39.3B EUR
75%
-33%
-33%
NL
argenx SE
XBRU:ARGX
38.1B EUR
89%
-15%
-5%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Madrigal Pharmaceuticals Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
6.1B USD
-119%
-79%
-99%
11 900%
FR
Pharnext SCA
OTC:PNEXF
6T USD
115%
-391%
275%
3 093%
US
Abbvie Inc
NYSE:ABBV
303.2B USD
56%
4%
15%
11%
US
Amgen Inc
NASDAQ:AMGN
146.3B USD
56%
5%
9%
10%
US
Gilead Sciences Inc
NASDAQ:GILD
114.4B USD
1%
0%
23%
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
108.8B USD
-3%
-2%
24%
-80%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
AU
CSL Ltd
ASX:CSL
132.9B AUD
16%
7%
12%
9%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
75B USD
17%
13%
13%
16%
US
Seagen Inc
F:SGT
39.3B EUR
-28%
-21%
-27%
-39%
NL
argenx SE
XBRU:ARGX
38.1B EUR
-3%
-3%
-9%
-22%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.